BioSpace News Archive

Recovery Force, LLC is pleased to announce the company has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the use of the Movement and Compressions (MAC) System, a novel, data-driven, mobility measurement device designed for hospital and home use.

RADx-rad STTR award will help the company develop their radical technology for regulatory approval and product launch.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

FDA Authorizes use of BPM31510 in Neo-Adjuvant and Concurrent Standard of Care Combination in Newly Diagnosed GBM Patients in a Phase 2 Clinical Trial

Potent antibodies shown to retain binding to major COVID-19-causing “South African” variant IONTAS now seeking development partners

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has received the official minutes from a Type B pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration (FDA) on its development plan for TNX-601 CR

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced that management will present an overview of AcelRx Pharmaceuticals, followed by a fireside chat with Dr. Pamela Palmer

It is with tremendous sadness that Cerner Corporation announces that Linda M. Dillman, a long-time and trusted board member, passed away on Saturday, March 13.

Sun Nuclear Corporation announced today that Australia’s Northern Sydney Cancer Centre (NSCC) is now a reference site for the SunCHECK™ Quality Management Platform.

Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, as evidenced by its recent phased launch of MYCAPSSA®